Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

"We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in 3D human tissue models, has reached an agreement to sell its FXR program, including the lead asset FXR314 ...

Photos from the 2025 Indianapolis Supercross, round nine of the Monster Energy AMA Supercross and SuperMotocross World ...

Not that quad exercises are only good for aesthetics. A study published in the Journal of Physical Therapy Science found that patients with knee osteoarthritis were able to soothe knee pain and ...

If Buffalo Sabres analyst Rob Ray was going to get hit by another puck during Tuesday’s game, it was going to have to be an errant puck. A very errant puck. During Saturday’s game between the ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism. Bile acids are natural ligands of FXR, which bind to the ...

After hours: March 20 at 4:07:01 PM EDT Loading Chart for QUAD ...